These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30510495)

  • 1. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis.
    Wang Y; Huang K; Chen J; Luo Y; Zhang Y; Jia Y; Xu L; Chen M; Huang B; Ni D; Li ZP; Feng ST
    Contrast Media Mol Imaging; 2018; 2018():6037273. PubMed ID: 30510495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
    Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
    BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
    Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST
    Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
    Sharma A; Das CJ; Makharia GK; Arora G; Kumar R
    Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
    Luboldt W; Hartmann H; Wiedemann B; Zöphel K; Luboldt HJ
    Mol Imaging; 2010 Dec; 9(6):351-8. PubMed ID: 21084031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
    Baumann T; Rottenburger C; Nicolas G; Wild D
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse Bone Metastases in Pancreatic Neuroendocrine Tumor Shown on Octreoscan.
    Adkins J; Lu Y
    Clin Nucl Med; 2019 Mar; 44(3):257-258. PubMed ID: 30624276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
    van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
    Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge.
    Granata V; Fusco R; Setola SV; Castelguidone ELD; Camera L; Tafuto S; Avallone A; Belli A; Incollingo P; Palaia R; Izzo F; Petrillo A
    Radiol Oncol; 2019 Oct; 53(4):373-387. PubMed ID: 31652122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
    Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastroenteropancreatic neuroendocrine tumors: impact of consistent contrast agent selection on radiologists' confidence in hepatic lesion assessment on restaging MRIs.
    Balthazar P; Shinagare AB; Tirumani SH; Jagannathan JP; Ramaiya NH; Khorasani R
    Abdom Radiol (NY); 2018 Jun; 43(6):1386-1392. PubMed ID: 28840281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CT and MRI findings of primary hepatic neuroendocrine neoplasm].
    Li JK; Wang M; Yuan J; Song ZG
    Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):600-606. PubMed ID: 28835083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.